The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Anthony H. Barnett

Diabetes Centre

Heart of England NHS Foundation Trust

Bordesley Green East

Birmingham

UK

[email]@heartofengland.nhs.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Diabetes Centre, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham, UK. 2006 - 2011
  • Heart of England National Health Service Foundation Trust (Teaching), University of Birmingham and Biomedical Research Unit, Birmingham, UK. 2006 - 2011
  • Department of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK. 2008 - 2009
  • Department of Diabetes, Obesity and Endocrinology, University of Birmingham and Birmingham Heartlands and Solihull NHS Trust, Bordesley Green East, United Kingdom. 2006 - 2007
  • Birmingham Heartlands Hospital, Birmingham, UK. 2007
  • University of Birmingham, Birmingham, UK. 2006

References

  1. New treatments for type 2 diabetes in the UK - an evolving landscape. Barnett, A.H. Prim. Care. Diabetes (2011) [Pubmed]
  2. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Barnett, A.H. Adv. Ther (2011) [Pubmed]
  3. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Barnett, A.H. Curr. Med. Res. Opin (2010) [Pubmed]
  4. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Barnett, A.H., Cradock, S., Fisher, M., Hall, G., Hughes, E., Middleton, A. Int. J. Clin. Pract. (2010) [Pubmed]
  5. Premature cardiovascular events and mortality in south Asians with type 2 diabetes in the United Kingdom Asian Diabetes Study - effect of ethnicity on risk. Bellary, S., O'Hare, J.P., Raymond, N.T., Mughal, S., Hanif, W.M., Jones, A., Kumar, S., Barnett, A.H. Curr. Med. Res. Opin (2010) [Pubmed]
  6. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Barnett, A.H. Vasc. Health. Risk. Manag (2009) [Pubmed]
  7. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). Barnett, A.H., Millar, H.L., Loze, J.Y., L'Italien, G.J., van Baardewijk, M., Knapp, M. Eur. Arch. Psychiatry. Clin. Neurosci (2009) [Pubmed]
  8. Translating science into clinical practice: focus on vildagliptin in combination with metformin. Barnett, A.H. Diabetes. Obes. Metab (2009) [Pubmed]
  9. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Barnett, A.H. Clin. Endocrinol. (Oxf) (2009) [Pubmed]
  10. The future of inhaled insulin and incretinmimetics in the management of diabetes. Barnett, A.H. Prim. Care. Diabetes (2008) [Pubmed]
  11. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Barnett, A.H., Krentz, A.J., Strojek, K., Sieradzki, J., Azizi, F., Embong, M., Imamoglu, S., Perusicová, J., Uliciansky, V., Winkler, G. Diabetes. Obes. Metab (2008) [Pubmed]
  12. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes. Barnett, A.H. Diab. Vasc. Dis. Res (2008) [Pubmed]
  13. Insulin for type 2 diabetes: choosing a second-line insulin regimen. Barnett, A., Begg, A., Dyson, P., Feher, M., Hamilton, S., Munro, N. Int. J. Clin. Pract. (2008) [Pubmed]
  14. Exenatide. Barnett, A. Expert. Opin. Pharmacother (2007) [Pubmed]
  15. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Barnett, A., Allsworth, J., Jameson, K., Mann, R. Curr. Med. Res. Opin (2007) [Pubmed]
  16. Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents. Barnett, A. Int. J. Clin. Pract. Suppl (2007) [Pubmed]
  17. Inhaled human insulin (Exubera): clinical profile and patient considerations. Barnett, A.H., Bellary, S. Vasc. Health. Risk. Manag (2007) [Pubmed]
  18. Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. Barnett, A.H., Lange, P., Dreyer, M., Serdarevic-Pehar, M. Int. J. Clin. Pract. (2007) [Pubmed]
  19. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Barnett, A.H., Burger, J., Johns, D., Brodows, R., Kendall, D.M., Roberts, A., Trautmann, M.E. Clin. Ther (2007) [Pubmed]
  20. Dosing of insulin glargine in the treatment of type 2 diabetes. Barnett, A. Clin. Ther (2007) [Pubmed]
  21. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. Barnett, A.H., Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, A., Hill, J., Millar, H., Peveler, R., Rees, A., Singh, V., Taylor, D., Vora, J., Jones, P.B. J. Psychopharmacol. (Oxford) (2007) [Pubmed]
  22. Insulin glargine in the treatment of type 1 and type 2 diabetes. Barnett, A.H. Vasc. Health. Risk. Manag (2006) [Pubmed]
  23. Prevention of loss of renal function over time in patients with diabetic nephropathy. Barnett, A. Am. J. Med. (2006) [Pubmed]
  24. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. Barnett, A. J. Am. Soc. Nephrol. (2006) [Pubmed]
  25. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Barnett, A.H., Dreyer, M., Lange, P., Serdarevic-Pehar, M. Diabetes. Care (2006) [Pubmed]
  26. How well do rapid-acting insulins work in obese individuals?. Barnett, A.H. Diabetes. Obes. Metab (2006) [Pubmed]
  27. Type 2 diabetes and cardiovascular risk in the UK south Asian community. Barnett, A.H., Dixon, A.N., Bellary, S., Hanif, M.W., O'hare, J.P., Raymond, N.T., Kumar, S. Diabetologia (2006) [Pubmed]
  28. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Barnett, A.H., Dreyer, M., Lange, P., Serdarevic-Pehar, M. Diabetes. Care (2006) [Pubmed]
  29. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Barnett, A. Int. J. Clin. Pract. (2006) [Pubmed]
 
WikiGenes - Universities